RPS6KB1 and gastric cancer: Our findings were further experimentally validated where AZD5363 demonstrated potent cytotoxic activities in PIK3CA-E542K-mutant gastric cancer cell-lines, subsequently downregulating PI3K pathway encoding molecules, including phosphorylation of mTOR, S6K, and 4E-BP1.